Gefitinib should be cautiously administered to poor performance status patients with non-small-cell lung cancer: Results from a prospective feasibility study

被引：9

作者：

Hotta, K

Inoue, A

Kiura, K

Ueoka, H

Tanimoto, M

Nukiwa, T

机构：

[1] Okayama Univ, Dept Med 2, Sch Med 2 5 1, Okayama 7008558, Japan

[2] Tohoku Univ, Dept Resp Oncol Mol Med, Inst Dev Aging & Canc, Aoba Ku, Sendai, Miyagi 9808575, Japan

[3] Okayama Univ, Sch Med, Okayama, Japan

[4] Tohoku Univ, Sendai, Miyagi 980, Japan

来源：

LUNG CANCER | 2005年 / 50卷 / 03期

关键词：

D O I：

10.1016/j.lungcan.2005.07.006

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：413 / 415

页数：3

共 6 条

[1] Activity of gefitinib in advanced non-small-cell lung cancer with very poor performance status [J].

Chang, GC ;

Chen, KC ;

Yang, TY ;

Yin, MC ;

Lin, CP ;

Kuo, BIT ;

Hsu, JY .

INVESTIGATIONAL NEW DRUGS, 2005, 23 (01) :73-77

[2]

DICKSON NR, 2004, P AN M AM SOC CLIN, V23, P634

[3] Dramatic effect of ZD1839 ('Iressa') in a patient with advanced nonsmall-cell lung cancer and poor performance status [J].

Fujiwara, K ;

Kiura, K ;

Ueoka, H ;

Tabata, M ;

Hamasaki, S ;

Tanimoto, M .

LUNG CANCER, 2003, 40 (01) :73-76

[4] Gefitinib in elderly and unfit patients affected by advanced non-small-cell lung cancer [J].

Gridelli, C ;

Maione, P ;

Castaldo, V ;

Rossi, A .

BRITISH JOURNAL OF CANCER, 2003, 89 (10) :1827-1829

[5] Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib [J].

Lynch, TJ ;

Bell, DW ;

Sordella, R ;

Gurubhagavatula, S ;

Okimoto, RA ;

Brannigan, BW ;

Harris, PL ;

Haserlat, SM ;

Supko, JG ;

Haluska, FG ;

Louis, DN ;

Christiani, DC ;

Settleman, J ;

Haber, DA .

NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (21) :2129-2139

[6]

ZINNER R, 2004, P AN M AM SOC CLIN, V23, P633

← 1 →